Hints and tips:
...James Kupiec, chief medical officer of PromisNeurosciences and the former head of Pfizer’s neuroscience unit, said Biogen’s reversal will “revitalise” the work pursuing the hypothesis that amyloid plaque...
...Michel Vounatsos, chief executive of Biogen, a large biotech company focused on neuroscience, says the valuations reflect what has been a “stellar” year for biology, citing advances in treating Huntington...
...Companies producing MS treatments include Biogen, Novartis, Teva and Sanofi....
...Concerns over side effects from the Biogen drug have since curbed some of this enthusiasm....
...Elan, the neuroscience business, on Tuesday became the latest to raise the prospect of a sale with the announcement of a “strategic business review”....
International Edition